# DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

> **NCT04337450** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **PENTA Foundation** · enrollment: 386 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dolutegravir (DTG) and lamivudine (3TC)
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT04337450
- **Lead sponsor:** PENTA Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-22
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337450, "DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT04337450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*